Zimmer Biomet Holdings (ZBH) Cost of Revenue (2009 - 2026)

Zimmer Biomet Holdings' Cost of Revenue history runs 18 years deep, the most recent figure standing at $576.2 million for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 4.8% year-over-year to $576.2 million in Q1 2026; TTM through Mar 2026 was $2.5 billion, a 13.07% increase from a year earlier, with the FY2025 full-year figure at $2.5 billion, up 13.81% from the prior year.
• Cost of Revenue fell to $576.2 million in Q1 2026 per ZBH's latest filing, from $792.4 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $792.4 million in Q4 2025 and bottomed at $488.2 million in Q3 2022.
• The 5-year median for Cost of Revenue is $538.6 million (2024), against an average of $550.8 million.
• Across the five-year window, Cost of Revenue retreated 3.02% in 2022 and jumped 35.06% in 2025, its largest moves.
• Year by year, Cost of Revenue stood at $520.3 million in 2022, then gained by 3.56% to $538.8 million in 2023, then grew by 8.89% to $586.7 million in 2024, then soared by 35.06% to $792.4 million in 2025, then dropped by 27.28% to $576.2 million in 2026.
• Per Business Quant, the three latest ZBH Cost of Revenue figures stand at $576.2 million (Q1 2026), $792.4 million (Q4 2025), and $559.3 million (Q3 2025).